Cargando…
Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome
Post-treatment Lyme disease syndrome (PTLDS) is a pain disorder for which there remains no gold standard treatment option. Here, we report a case of PTLDS in a female patient whose pain was refractory to treatment options such as radiofrequency ablation, vitamin infusion therapy, opioid analgesics,...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571854/ https://www.ncbi.nlm.nih.gov/pubmed/28860873 http://dx.doi.org/10.2147/IMCRJ.S137975 |
_version_ | 1783259420201844736 |
---|---|
author | Hanna, Ashraf F Abraham, Bishoy Hanna, Andrew Smith, Adam J |
author_facet | Hanna, Ashraf F Abraham, Bishoy Hanna, Andrew Smith, Adam J |
author_sort | Hanna, Ashraf F |
collection | PubMed |
description | Post-treatment Lyme disease syndrome (PTLDS) is a pain disorder for which there remains no gold standard treatment option. Here, we report a case of PTLDS in a female patient whose pain was refractory to treatment options such as radiofrequency ablation, vitamin infusion therapy, opioid analgesics, and other pharmacotherapies. The patient commenced an experimental intravenous ketamine infusion therapy at the Florida Spine Institute (Clearwater, FL, USA) and achieved relief from her chronic pain, an improved quality of life, reduced depression and suicidal ideation, and reduced opioid consumption. |
format | Online Article Text |
id | pubmed-5571854 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-55718542017-08-31 Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome Hanna, Ashraf F Abraham, Bishoy Hanna, Andrew Smith, Adam J Int Med Case Rep J Case Report Post-treatment Lyme disease syndrome (PTLDS) is a pain disorder for which there remains no gold standard treatment option. Here, we report a case of PTLDS in a female patient whose pain was refractory to treatment options such as radiofrequency ablation, vitamin infusion therapy, opioid analgesics, and other pharmacotherapies. The patient commenced an experimental intravenous ketamine infusion therapy at the Florida Spine Institute (Clearwater, FL, USA) and achieved relief from her chronic pain, an improved quality of life, reduced depression and suicidal ideation, and reduced opioid consumption. Dove Medical Press 2017-08-18 /pmc/articles/PMC5571854/ /pubmed/28860873 http://dx.doi.org/10.2147/IMCRJ.S137975 Text en © 2017 Hanna et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Case Report Hanna, Ashraf F Abraham, Bishoy Hanna, Andrew Smith, Adam J Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome |
title | Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome |
title_full | Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome |
title_fullStr | Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome |
title_full_unstemmed | Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome |
title_short | Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome |
title_sort | effects of intravenous ketamine in a patient with post-treatment lyme disease syndrome |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571854/ https://www.ncbi.nlm.nih.gov/pubmed/28860873 http://dx.doi.org/10.2147/IMCRJ.S137975 |
work_keys_str_mv | AT hannaashraff effectsofintravenousketamineinapatientwithposttreatmentlymediseasesyndrome AT abrahambishoy effectsofintravenousketamineinapatientwithposttreatmentlymediseasesyndrome AT hannaandrew effectsofintravenousketamineinapatientwithposttreatmentlymediseasesyndrome AT smithadamj effectsofintravenousketamineinapatientwithposttreatmentlymediseasesyndrome |